Evidence map›Paper›PMID 41945165›Full record

ReviewImmunologic research2026

Subcutaneous Sweet Syndrome as an uncommon mucocutaneous manifestation in systemic lupus erythematosus: a case report and literature review.

Erik Cimé-Aké, David Arriaga Escamilla, Javier Ríos-Valencia, Marcela Saeb-Lima, Hilda Fragoso-Loyo

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Erik Cimé-AkéDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga 15, Belisario Domínguez Sección XVI, Z.C. 14080, Tlalpan, Mexico City, Mexico.ORCID http://orcid.org/0000-0002-7012-8419
David Arriaga EscamillaInternal Medicine, Universidad Justo Sierra, Mexico City, Mexico.
Javier Ríos-ValenciaDepartment of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.ORCID http://orcid.org/0000-0002-7965-5872
Marcela Saeb-LimaDepartment of Pathology, Centro Médico ABC Campus Santa Fe, Mexico City, Mexico.ORCID http://orcid.org/0000-0002-3157-6665
Hilda Fragoso-LoyoDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga 15, Belisario Domínguez Sección XVI, Z.C. 14080, Tlalpan, Mexico City, Mexico. hfragosol@gmail.com.ORCID http://orcid.org/0000-0001-6576-1159

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Sweet Syndrome (SS) as a mucocutaneous manifestation of systemic lupus erythematosus (SLE) has been rarely reported in the literature. The subcutaneous variant of SS in SLE patients is extremely rare. We present a case of a subcutaneous SS occurring as a manifestation of SLE and we discuss the findings reported in the literature regarding this association. The patient was a 31-year-old woman with a recently diagnosis of SLE. On admission she presented with malaise, fever, and skin lesions consisting with tender and warmth large plaques with a violaceous erythema on the right thigh. Laboratory studies showed leukocytosis, neutrophilia, elevated high-sensitive C-reactive protein, hypocomplementemia and increased levels of anti-dsDNA. Others differential diagnosis were ruled out. The skin biopsy revealed a superficial and deep perivascular and periadnexal infiltrate, with neutrophils surrounding adipocytes, concluding the diagnosis of subcutaneous SS. She had a good response to treatment with prednisone 0.5 mg/kg/day, and dapsone 100 mg/day. A structured literature search was performed in PubMed, Web of Science and Scopus, identifying 17 published cases of SS associated with SLE. SS in SLE tends to occur early in the disease course and typically presents as painful violaceous erythematous plaques, accompanied by constitutional SLE manifestations and elevated anti-dsDNA and anti-Sm levels. SS should be considered as a possible manifestation in SLE patients.

Indexed as

Lupus Erythematosus, SystemicSkinSweet SyndromeAdultBiopsyDapsoneFemaleHumansPrednisoneDapsonePrednisoneLupus erythematosus, systemicNeutrophilic dermatoses, case reportSkin manifestationsSweet syndrome

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.